A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Schober's test tests the flexion of the lower back. Multiple joint inspection Musculoskeletal Examination Screening Musculoskeletal Exam (SMSE) - a rapid assessment of structure and function General Musculoskeletal Exam (GMSE) - a comprehensive assessment of joint inflammation Regional Musculoskeletal Exam (RMSE) - focused assessments of structure, function and inflammation combined with special testing
In patients on a vitamin K antagonist such as warfarin with supratherapeutic INR but INR less than 10 and no bleeding, it is enough to lower the dose or omit a dose, monitor the INR and resume the vitamin K antagonist at an adjusted lower dose when the target INR is reached. For people who need rapid reversal of the vitamin K antagonist – such as due to serious bleeding – or who need emergency surgery, the effects of warfarin can be reversed with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP).
Captain John Macarthur: pioneer of the Merino wool industry in Australia, founder of the Australian Agricultural Company, and large landowner at Camden. Captain William Cox: builder of the road across the Blue Mountains, important pastoralist in the Hawkesbury and Bathurst regions. Captain John Piper: significant land-holder in Sydney and Bathurst. Captain Edward Abbott: important colonist of Tasmania. Lieutenant William Lawson: explorer across the Blue Mountains and prominent land-holder in the Mudgee region. Lieutenant Anthony Fenn Kemp: significant colonist of Tasmania. Lieutenant Archibald Bell Sr.: important landowner in the Hawkesbury region. Surgeon John Harris: extensive property owner in Sydney and the Bathurst region. Lieutenant Nicholas Bayly: large land-holder in Cabramatta region.
== Classification == Described primarily based on the type of biochemical group transferred, transferases can be divided into ten categories (based on the EC Number classification). These categories comprise over 450 different unique enzymes. In the EC numbering system, transferases have been given a classification of EC2. Hydrogen is not considered a functional group when it comes to transferase targets; instead, hydrogen transfer is included under oxidoreductases, due to electron transfer considerations.
=== Future development === Because most of MNPs applications are still under development, it is important to note the long effect of the efficiency of the drug deliveries. More research is needed to get information of what molecule can be delivered using MNPs. Disposal is also an important topic, as the small plastic backing may contribute to water pollution remembering the compact size can be easily carried away by wind and water without proper disposal.
Sources: en.wikipedia.org
== Career == Principal Scientist SCIEX - 1980-2005 Associate Professor (CLTA) at the University of Toronto, first in the Institute of Biomaterials and Biomedical Engineering (2005–2008) and then in Chemistry 2008–2013. President DVS Sciences 2004 - 2015 (acquired by Fluidigm in 2014) Adjunct Professor at York University in the Department of Chemistry 2015–2018
==== Actions ==== Compound 22 is a low-potency antagonist of the trace amine-associated receptor 1 (TAAR1). It has shown significant inhibition of TAAR1 signaling at a concentration of 100 μM in vitro. The drug's IC50Tooltip half-maximal inhibitory concentration value for TAAR1 antagonism is unknown but is greater than 100 μM. Compound 22 was also screened for off-target activity at 47 targets at a concentration of 10 μM. The screened targets included monoamine receptors, monoamine transporters, histamine receptors, muscarinic acetylcholine receptors, glutamate receptors, GABA receptors, opioid receptors, and sigma receptors. There were five hits (>50% binding inhibition), which included the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET), as well as the sigma σ1 and σ2 receptors. Its affinities (Ki) were 1,800 nM for the SERT, 1,053 nM for the DAT, 1,902 nM for the NET, 276 nM for the sigma σ1 receptor, and 412 nM for the sigma σ2 receptor. Although compound 22 bound with significant affinity to the DAT, it did not inhibit dopamine reuptake and did not interfere with cocaine-induced dopamine reuptake inhibition at concentrations of up to 100 μM.
== Chemistry == Suvorexant is a small-molecule compound. The chemical name of suvorexant is [(7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone. Its molecular formula is C23H23N6O2Cl and its molecular weight is 450.92 g/mol. Suvorexant is a white to off-white powder and is lipophilic and insoluble in water. It is structurally related to other orexin receptor antagonists like lemborexant, daridorexant, and seltorexant.
Geography, demography, and tradition contributed to this outcome but did not determine it. It took men, responding unpredictably to circumstances, to forge the chain of causation; and it took [Stalin] in particular, responding predictably to his own authoritarian, paranoid, and narcissistic predisposition, to lock it into place. According to Leffler, the most distinctive feature of We Now Know is the extent to which Gaddis "abandons post-revisionism and returns to a more traditional interpretation of the Cold War". Gaddis is now widely seen as more "orthodox" than "post-revisionist". The revisionist Bruce Cumings had a high-profile debate with Gaddis in the 1990s, where Cumings criticized post-revisionism generally and Gaddis in particular as moralistic and lacking in historical rigor. Cumings urged post-revisionists to employ modern geopolitical approaches like world-systems theory in their work. Other post-revisionist accounts focus on the importance of the settlement of the German Question in the scheme of geopolitical relations between the United States and the Soviet Union.
Sources: en.wikipedia.org
Carnitine is an essential cofactor for mitochondrial transport of long‑chain fatty acids (a major lipid class) into the matrix for β‑oxidation. gamma-aminobutyric acid is a neurotransmitter. 5-HTP (5-hydroxytryptophan) is used for experimental treatment of depression. L-DOPA (L-dihydroxyphenylalanine) for Parkinson's treatment, Eflornithine inhibits ornithine decarboxylase and used in the treatment of sleeping sickness. Canavanine, an analogue of arginine found in many legumes is an antifeedant, protecting the plant from predators. Mimosine found in some legumes, is another possible antifeedant. This compound is an analogue of tyrosine and can poison animals that graze on these plants. However, not all of the functions of other abundant nonstandard amino acids are known.
UR (Uitsluitend Recept): prescription only UA (Uitsluitend Apotheek): pharmacist only UAD (Uitsluitend Apotheek of Drogist): pharmacist or drugstore only AV (Algemene Verkoop): may be sold in general stores A drug that is UA may be sold OTC but only by pharmacists. The drug can be on the shelves like any other product. Examples are domperidone, 400 mg ibuprofen up to 50 tablets and dextromethorphan. A drug that is UAD can also be sold at drugstores which are stores where no prescription can be filled. The drugs are usually on the shelves, and the store also sells items like toys, gadgets, perfumes and homeopathic products. The drugs in this category have limited risk and addiction potential. Examples are naproxen and diclofenac in small amounts, cinnarizine, 400 mg ibuprofen up to 20 tablets and also 500 mg paracetamol up to 50 tablets. Drugs in the AV category can be sold at supermarkets, gas stations, etc. and include only drugs with minimal risk to the public, like paracetamol up to 20 tablets, 200 mg ibuprofen up to 10 tablets, cetirizine and loperamide.
==== Legal challenges ==== In Glossip v. Gross, attorneys for three Oklahoma inmates argued that midazolam could not achieve the level of unconsciousness required for surgery, meaning severe pain and suffering was likely. They argued that midazolam was cruel and unusual punishment and thus contrary to the Eighth Amendment to the United States Constitution. In June 2015, the U.S. Supreme Court ruled that they had failed to prove that midazolam was cruel and unusual when compared to known, available alternatives. The state of Nevada is also known to use midazolam in execution procedures. In July 2018, one of the manufacturers accused state officials of obtaining the medication under pretences. This incident was the first time a drug company successfully, though temporarily, halted an execution. A previous attempt in 2017, to halt an execution in the state of Arizona by another drug manufacturer was not successful.
3 April Five employees at the National Hurricane Center publish a tropical cyclone report (TCR) on Hurricane Ian, which officially upgrades the hurricane from a Category 4 to a Category 5 on the Saffir–Simpson scale. The TCR also stated that Hurricane Ian caused, with 90% confidence, $112.9 billion worth of damage to the United States, which made Ian the third-costliest United States hurricane on record as well as the costliest hurricane to strike Florida on record. An unexplained rise of emissions of five chlorofluorocarbons (CFCs), successfully banned by the Montreal Protocol of 1989, is reported. Their climate impact in 2020 is roughly equivalent to that of the CO2e from Denmark in 2018. A study affirms and explains why a moderate decrease in body temperature extends lifespan. 5 April The NOAA reports that greenhouse gases continued to increase rapidly in 2022 and that CO2 levels in the atmosphere are now the highest in 4.3 million years. An umbrella review summarizes scientific results on the extensive health effects of added-sugar foods and makes recommendations such as limiting sugar-sweetened beverages which are "the largest source of added sugars" and developing of policy such as advertising restrictions. 6 April – A study shows neurons take up glucose (from food) and metabolize it by glycolysis. There was only limited research on how neurons get their energy in the context of links between glucose metabolism and cognition (brain health and performance). 10 April – A study expands upon the role of elites' unsustainable consumption in urban water crises.
==== Frogs (Anura) ==== Taudactylus pleione, Kroombit tinker frog (2023) Leptobrachium leishanense, Leishan Moustache toad (2019) Limnodynastes dumerilii dumerilii, Eastern banjo frog (2020) Nanorana parkeri, High Himalaya frog (2015) Oophaga pumilio, Strawberry poison-dart frog (2018) Platyplectrum ornatum, Ornate burrowing frog (2021) Pyxicephalus adspersus, African bullfrog (2018) Rana [Lithobates] catesbeiana, North American bullfrog (2017) Rana kukunoris, Plateau brown frog (2023) Rhinella marina, Cane toad (2018) Vibrissaphora ailaonica, Moustache toad (2019) Xenopus tropicalis, western clawed frog (2010) Mixophyes australis, Australian southern stuttering frog (2024) Spea multiplicata, spadefoot toad (2019) Pelobates cultripes, Western spadefoot toad (2022) Dendrobates tinctorius, Dyeing poison frog (2024) Ranitomeya imitator, mimic poison frog (2024) Phyllobates terribilis, Dart-poison frog (2025) Staurois parvus, foot-flagging frog (2023)
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.